Home    Back

Adderall xr    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica2

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02676739
(ClinicalTrials.gov)		May 20, 20163/2/2016Adderall XR and Cognitive Impairment in MSA Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MSMultiple SclerosisDrug: Adderall XRSarah MorrowNULLRecruiting18 Years59 YearsAll180Phase 2;Phase 3Canada
2NCT01667484
(ClinicalTrials.gov)		September 201213/8/2012Adderall XR and Processing Speed in Multiple Sclerosis (MS)Does Adderall XR Improve Processing Speed in Cognitively Impaired MS Patients?Impaired Processing Speed;Cognitive Impairment;Multiple SclerosisDrug: Adderall XR 5mg;Drug: Adderall XR 10 mg;Drug: PlaceboLondon Health Sciences CentreNULLCompleted18 Years59 YearsBoth70Phase 2;Phase 3Canada